- Home
- USA vs SLNO Comparison
USA vs SLNO Comparison
Compare USA & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USA | SLNO |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.5B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | USA | SLNO |
|---|---|---|
| Price | $6.32 | $49.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $110.90 |
| AVG Volume (30 Days) | 880.5K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $98,675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $155.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.62 | $41.50 |
| 52 Week High | $7.09 | $90.32 |
Technical Indicators
Market Signals| Indicator | USA | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 62.73 | 45.79 |
| Support Level | $6.11 | $47.01 |
| Resistance Level | $6.20 | $50.95 |
| Average True Range (ATR) | 0.07 | 2.40 |
| MACD | 0.02 | 0.21 |
| Stochastic Oscillator | 100.00 | 25.22 |
Price Performance
Historical ComparisonAbout USA Liberty All-Star Equity Fund
Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.